- Brain-gut axis treatment developer PureTech Health said it had acquired the remaining 10% of Ariya Therapeutics that it did not already own.

The company had been renamed LYT and would its four technology platforms in immuno-oncology, synthetic lymphatic targeting chemistry, milk exosomes and meningeal lymphatics.

The acquired minority interests were previously held by the co-inventors of the four platforms and associated universities and advisors.

To fund the acquisition, PureTech said it would issue 2,126,338 new ordinary shares of 1p each and grant options to the co-inventors of and advisors to the four platforms to purchase 2,147,295 ordinary shares under the PureTech Health performance share plan.

Story provided by